Breast cancer is the most prevalent malignancy among women globally. Early diagnosis and treatment improvements are leading to a growing population of survivors. This has increased the risk of developing contralateral breast cancer (CBC), a distinct occurrence in the opposite breast of a previously diagnosed patient. The treatment options for breast cancer are often mas-tectomy or lumpectomy. Patients with lumpectomy frequently undergo a contralateral reduc-tion procedure to achieve more symmetry after the primary breast cancer surgery. The reduc-tion specimen is usually routinely examined by pathology to check for malignancies. The exci-sion in pieces and the absence of specific markers or ink make an examination of tumor size and margin status more challenging, impacting treatment decisions. A new protocol introduced in July 2022 seeks to improve diagnostic precision and treatment planning by excision in toto, marking, and inking excised reduction tissue to examine and treat potential CBC more effectively.

Background: Although several studies have been conducted on the use of Artificial Intelligence (AI) in mammography (MG), research focusing on the diagnosis of metachronous bilateral breast cancer (BC), which is typically more challenging to diagnose, remains limited. This study assessed whether AI could enhance the detection of BC, achieving earlier or more accurate diagnoses than radiologists in cases of metachronous contralateral BC. Methods: The study included patients who underwent unilateral BC surgery and subsequently developed contralateral BC during follow-up. We evaluated the capability of the AI-supported MG diagnostic system FxMammo™ (FathomX Pte Ltd, Singapore) to diagnose BC more accurately or earlier than radiologists' assessments. This evaluation was supplemented by reviewing MG readings by radiologists. Results: Out of 1,101 patients who underwent surgery, 10 patients who had initially received a partial mastectomy and later developed contralateral BC were analyzed. The AI system identified malignancies in 6 cases (60%), while radiologists identified 5 cases (50%). Notably, two cases (20%) were diagnosed solely by the AI system. Additionally, for these cases, the AI system had identified malignancies a year prior to the conventional diagnosis. Conclusions: This study highlights the AI system's effectiveness in diagnosing metachronous contralateral BC via MG. In some cases, the AI system consistently diagnosed cancer at earlier than radiological assessments.

The present study compared the contralateral suppression and the amplitude of distortion product otoacoutsic emissions (DPOAEs) between smokers and non-smokers to determine the influence of smoking. Thirty smokers and thirty non-smokers within the age range of 18-40 years with a normal hearing sensitivity were considered for the study. For both the groups, DPOAEs were measured and the efferent auditory system functioning was measured by presenting the white noise of 50 dB HL to the contralateral side, while recording the DPOAEs. There was no significant effect of age on the amplitude of DPOAEs in both the groups. However, there were significant differences in the amplitude of DPOAEs between smokers and non-smokers. The amount of suppression and DPOAE amplitude were reduced in smokers when compared to non-smokers. The study found no significant correlation between the amount of smoking and amount of suppression between smokers and non-smokers. However, there were significant correlations between the amount of smoking and DPOAE at low and mid frequencies between smokers and non-smokers. Therefore, the present study highlights the increased damage to the efferent auditory system risk and the smoking ill-effects on the efferent auditory system.